Luyan Pharma Co.,Ltd. (SHE:002788)

Luyan Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	513.85	576.85	606.3	594.19	415.43	596.92
Cash & Short-Term Investments	513.85	576.85	606.3	594.19	415.43	596.92
Cash Growth	-7.30%	-4.86%	2.04%	43.03%	-30.40%	39.16%
Accounts Receivable	6,247	5,951	5,673	5,849	5,101	3,935
Other Receivables	118.01	108.33	94.59	87.49	117.17	269.68
Receivables	6,365	6,059	5,768	5,937	5,218	4,205
Inventory	2,571	2,865	2,574	2,549	2,275	2,028
Prepaid Expenses	0.06	0.02	0.25	0.33	0.08	0.25
Other Current Assets	395.88	369.1	370.33	668.17	414.12	378.69
Total Current Assets	9,846	9,870	9,319	9,748	8,322	7,209
Property, Plant & Equipment	1,977	1,928	1,653	1,425	1,037	845.53
Long-Term Investments	52.45	53.41	48.85	34.21	31.3	0.3
Goodwill	289.28	289.28	288.65	289.45	289.45	283.88
Other Intangible Assets	356.51	361.09	355.16	176.93	167.81	113.23
Long-Term Deferred Tax Assets	78.54	75.79	66.37	54.71	43.39	35.11
Long-Term Deferred Charges	26.78	29.04	28.58	28.96	32.82	33.73
Other Long-Term Assets	28.41	31.5	34.46	26.08	68.98	50.73
Total Assets	12,655	12,639	11,794	11,784	9,993	8,571
Accounts Payable	3,848	4,004	3,444	3,258	2,410	2,006
Accrued Expenses	74.7	86.74	98.53	119.54	111.6	103.73
Short-Term Debt	3,929	3,875	3,990	4,455	4,130	3,362
Current Portion of Long-Term Debt	323.44	293.91	171.26	58.25	47.31	21.31
Current Portion of Leases	52.34	46.67	43.54	37.98	41.69	-
Current Income Taxes Payable	29.93	36.67	43.98	43.47	45.42	44.26
Current Unearned Revenue	36.39	30.72	22.38	31.78	10.57	18.73
Other Current Liabilities	401.49	232.47	211.84	296.53	217.69	353.98
Total Current Liabilities	8,695	8,605	8,026	8,301	7,015	5,910
Long-Term Debt	579.29	648.41	578.63	475.04	226.6	116.94
Long-Term Leases	89.28	87.33	74.33	53.86	40.37	-
Long-Term Unearned Revenue	38.45	38.83	39.76	41.2	41.85	11.5
Long-Term Deferred Tax Liabilities	6.38	6.54	6.81	7.07	7.34	7.63
Other Long-Term Liabilities	38.07	60.14	90.98	114.97	101.17	77.27
Total Liabilities	9,446	9,447	8,817	8,993	7,433	6,124
Common Stock	388.52	388.52	388.52	388.52	388.52	388.52
Additional Paid-In Capital	616.24	617.54	631.05	653.6	656.37	752.07
Retained Earnings	2,170	2,152	1,923	1,676	1,447	1,240
Comprehensive Income & Other	4.01	4.24	3.84	2.82	-0.5	0.49
Total Common Equity	3,179	3,162	2,946	2,721	2,492	2,381
Minority Interest	29.03	29.67	30.68	69.84	68.47	65.96
Shareholders' Equity	3,208	3,192	2,977	2,791	2,560	2,447
Total Liabilities & Equity	12,655	12,639	11,794	11,784	9,993	8,571
Total Debt	4,973	4,951	4,858	5,080	4,486	3,500
Net Cash (Debt)	-4,459	-4,374	-4,252	-4,486	-4,071	-2,903
Net Cash Per Share	-11.52	-11.26	-10.99	-11.57	-10.51	-8.06
Filing Date Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Total Common Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Working Capital	1,151	1,265	1,292	1,447	1,307	1,298
Book Value Per Share	8.18	8.14	7.58	7.00	6.41	6.13
Tangible Book Value	2,533	2,512	2,302	2,254	2,034	1,984
Tangible Book Value Per Share	6.52	6.47	5.93	5.80	5.24	5.11
Buildings	1,477	1,443	1,001	899.38	858.76	816.23
Machinery	283.77	278.43	259.22	214.51	196.8	182.21
Construction In Progress	504.69	471.48	616.59	509.06	139.74	57.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.